



RNS Number : 1942U  
Roquefort Therapeutics PLC  
27 June 2024

27 June 2024

**Roquefort Therapeutics plc**  
**("Roquefort Therapeutics" or the "Company")**

**Results of AGM**

Roquefort Therapeutics (LSE:ROQ, OTCQB: ROQAF), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth immuno-oncology market, is pleased to announce that at the Company's Annual General Meeting ("**AGM**") held earlier today, all resolutions proposed were duly passed.

The resolutions were put to shareholders via a poll, the results of which were as follows:

<b>Resolution</b>	<b>Poll Results For</b>	<b>Against</b>	<b>Total Votes Cast</b>	<b>Total Votes Withheld*</b>
1 Shares	24,948,663	-	24,948,663	-
%	100.00%	-		
2 Shares	24,943,456	-	24,943,456	5,191
%	100.00%	-		
3 Shares	24,943,472	-	24,943,472	5,191
%	100.00%	-		
4 Shares	20,529,178	-	20,529,178	4,419,485
%	100.00%	-		
5 Shares	24,948,663	-	24,948,663	-
%	100.00%	-		
6 Shares	24,948,663	-	24,948,663	-
%	100.00%	-		
7 Shares	24,938,750	9,913	24,948,663	-
%	99.96%	0.04%		
8 Shares	24,938,730	9,933	24,948,663	-
%	99.96%	0.04%		

*\* Votes withheld are not counted in the calculation of the proportion of votes for and against a resolution.*

The total number of ordinary shares in issue on 25 June 2024, the deadline for casting votes by proxy in advance of the AGM, was 129,149,998 shares. 19.3% of voting capital was instructed in respect of the resolutions put to the AGM.

## Enquiries:

<b>Roquefort Therapeutics plc</b> Stephen West (Chairman) / Ajan Reginald (CEO)	+44 (0)20 3918 8633
<b>SP Angel Corporate Finance LLP (Broker)</b> Jeff Keating / David Hignell / Vadim Alexandre	+44 (0) 20 3470 0470
<b>Buchanan (Public Relations)</b> Ben Romney / Jamie Hooper / George Beale	+44 (0)20 7466 5000
<b>Peak IR (Investor Relations)</b> Seb Wykeham	+33 (0)7 44 44 15 42

LEI: 254900P4SISIWOR9RH34

## About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing first in class drugs in the high value and high growth immunoncology segment prior to partnering or selling to big pharma.

Roquefort Therapeutics' portfolio consists of five novel, patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of five best-in-class medicines consists of:

- Midkine antibodies with significant *in vivo* efficacy and toxicology studies;
- Midkine RNA therapeutics with novel anti-cancer gene editing action;
- Midkine mRNA therapeutics with novel anti-cancer approach;
- STAT-6 siRNA therapeutics targeting solid tumours with significant *in vivo* efficacy; and
- MK cell therapy with direct and NK-mediated anti-cancer action

For further information on Roquefort Therapeutics, please visit [www.roquefortplc.com](http://www.roquefortplc.com) and @RoquefortTherap on X (formerly Twitter).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RAGFLFSLREIDFIS

Anonymous (not verified)

Results of AGM

<http://www.DigitalLook.com>

34391805

A

Thu, 06/27/2024 - 12:46

LSE RNS

Results and Trading Reports

ROQ